AvevoRx ANNOUNCES ENTRY INTO ALPHA-1 PROTEINAISE INHIBITOR MARKET, INCREASING THERAPEUTIC ACCESS FOR PATIENTS WITH RARE FORM OF CONGENITAL EMPHYSEMA
“AvevoRx brings the knowledge and infrastructure to provide services and programs typically expected of much bigger pharmacies while leveraging our adaptability and commitment to delivering an extraordinarily customized, personal patient experience.” GREENSBORO, N.C. (PRWEB) January 27, 2023 AvevoRx, a national, independent provider of specialty infusion pharmacy services, has announced it will provide Alpha-1 proteinase inhibitor […]
